Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + bevacizumab + pyrotinib
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of three anti-cancer agents: anlotinib, bevacizumab, and pyrotinib. Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor that targets EGFR (HER1), HER2, and HER4. It works by binding competitively to the ATP binding domain of the EGFR family, inhibiting phosphorylation of tyrosine kinase and blocking downstream RAS/RAF/MEK/MAPK and PI3K/AKT signaling pathways, thereby inhibiting tumor cell growth. Pyrotinib was developed in China and received conditional approval there for use in combination with capecitabine for HER2-positive advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy.
- Other names
- BLTNIrenePyrotinib maleatePyrroltinib maleate
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFA (Vascular endothelial growth factor A)EGFR T790M (Epidermal growth factor receptor T790M mutant)VEGFR4 (Vascular endothelial growth factor Receptor-3)FGFR (FGFR family)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on anlotinib + bevacizumab + pyrotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + bevacizumab + pyrotinib.